Abstract
Colorectal cancer is one of the most prevalent cancers worldwide. We have thus focused on studies on the association of genetic polymorphisms with treatment response and adverse effects in colorectal cancer patients. This review highlights the inter-individual and inter-population genetic variations in ABC transporters and their association with variability in drug response. Several studies report the association of specific ABC transporter gene polymorphisms with the risk of developing colorectal carcinoma and the clinical outcomes in patients undergoing chemotherapy. It is important to understand genetic polymorphisms and genetic profiling for colorectal cancer patients in the context of personalized medication. This review is built on a comprehensive knowledge of the pharmacogenetics of colorectal carcinoma with a special focus on ABC polymorphism.